Ranbaxy receives approval to mkt Loperamide Hydrochloride

Published on Mon, Sep 11, 2006 at 15:00 |  Source : Moneycontrol.com

Updated at Mon, Sep 11, 2006 at 16:31  

39737 Investors following Ranbaxy Labs. Share this News with them.
0
0
Share on Tumblr

RELATED NEWS

ALSO READ

Ranbaxy Laboratories Limited (RLL), announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Loperamide Hydrochloride and Simethicone Tablets, 2 mg/125 mg (OTC).  The Office of Generic Drugs, U.S. Food and Drug Administration, has determined Ranbaxy's Loperamide Hydrochloride and Simethicone Tablets, 2 mg/125 mg (OTC) to be bioequivalent to the reference listed drug (RLD) ImodiumÒ Advanced Caplets, 2 mg/125 mg (OTC) of McNeil Consumer and Specialty Pharmaceuticals, a Division of McNeil PPC, Inc. (McNeil).

 

Loperamide Hydrochloride and Simethicone Tablets (OTC) are indicated for controlling symptoms of diarrhea plus bloating, pressure, and cramps commonly referred to as gas.  Total sales of $25.3 million (IRI - MAT:  June 2006) were achieved for this product that is sold in the OTC market.

 

According to Robert Haywood, Senior Director of OTC Sales and Marketing of Ohm Laboratories Inc., "Ohm will again be a leading participant in the launch of another successful and proven Loperamide formulation.   This will be marketed on a 180-day exclusive basis in the private label/store brand segment of major U.S. retailers and wholesalers.  Ohm plans to ship when sufficient supplies are produced to meet the demands of the marketplace."

 

 

Contd on page 2..

  

Trending News

Business News

Sony to roll-out ICS update next week, Xperia PLAY gets the boot
Reebok execs named in Rs 870 cr fraud denied anticipatory bail "Reebok execs named in Rs 870 cr fraud denied anticipatory bail"

Live Updates: KKR favourites in last-over battle

Rel Comm Q4 Cons Net Revenue Up 5% At `5,310 Cr (QoQ)

The latest earning numbers FIRST on CNBC-TV18
Videos

May 25 2012, 22:26

NHPC posts profit amid capacity addition, delay woes

- in Results Boardroom

Interviews

May 27 2012, 11:52 | Source: CNBC-TV18

Expect to maintain EBIDTA margin ahead: Wockhardt  

May 27 2012, 11:00 | Source: CNBC-TV18

e-commerce market in India: What's in store?  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!